DAN Stock Overview
A biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
DanCann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.0002 |
| 52 Week High | DKK 0.012 |
| 52 Week Low | DKK 0.0002 |
| Beta | 2.11 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -91.30% |
| 3 Year Change | -99.97% |
| 5 Year Change | n/a |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| DAN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 2.3% |
| 1Y | -91.3% | -12.6% | 11.9% |
Return vs Industry: DAN underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: DAN underperformed the German Market which returned 11.9% over the past year.
Price Volatility
| DAN volatility | |
|---|---|
| DAN Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DAN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine DAN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Jeppe Rasmussen | www.dancann.com |
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros.
DanCann Pharma A/S Fundamentals Summary
| DAN fundamental statistics | |
|---|---|
| Market cap | €454.40k |
| Earnings (TTM) | -€7.76m |
| Revenue (TTM) | €1.08m |
0.4x
P/S Ratio-0.1x
P/E RatioIs DAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAN income statement (TTM) | |
|---|---|
| Revenue | DKK 8.02m |
| Cost of Revenue | DKK 9.29m |
| Gross Profit | -DKK 1.27m |
| Other Expenses | DKK 56.64m |
| Earnings | -DKK 57.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | -15.79% |
| Net Profit Margin | -721.62% |
| Debt/Equity Ratio | 0% |
How did DAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 21:37 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DanCann Pharma A/S is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Augustsson | Carlsquare AB |
| Jonatan Andersson | Carlsquare AB |
| Fredrik Nilsson | Carlsquare AB |